Zagars Gunar K, Ballo Matthew T, Pisters Peter W T, Pollock Raphael E, Patel Shreyaskumar R, Benjamin Robert S
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer. 2003 May 15;97(10):2544-53. doi: 10.1002/cncr.11367.
Patients with localized soft tissue sarcoma (STS) who present to specialist centers after undergoing apparent macroscopic total resection often have a significant incidence of residual tumor and may benefit from reresection of the tumor bed. The potential benefits of such reresection have not been documented adequately.
The clinicopathologic features and disease outcome for 666 consecutive patients with localized STS who presented after undergoing apparent macroscopic total tumor resection were analyzed to elucidate the relative merits of reresection. Actuarial univariate and multivariate methods were used to compare disease outcome of patients who presented with positive or uncertain microscopic resection margins according to whether they underwent reresection. All patients received adjuvant radiation therapy.
Two hundred and ninety-five patients underwent reresection of their tumor bed, and residual tumor was found in 136 patients (46%), including macroscopic tumor in 73 patients (28%). Final resection margins among patients who underwent reresection were negative in 257 patients (87%), positive in 35 patients (12%), and uncertain in 3 patients (1%). Patients who did not undergo reresection had final margins that were negative in 117 patients (32%), positive in 47 patients (13%), and uncertain in 207 patients (56%). Local control rates at 5 years, 10 years, and 15 years for patients who underwent reresection were 85%, 85%, and 82%, respectively; for patients who did not undergo reresection, the respective local control rates were 78%, 73%, and 73% (P = 0.03). Reresection remained a significant determinant of local control when other prognostic factors were incorporated into a multivariate proportional hazards regression analysis. A similar beneficial effect of reresection was found for metastasis free survival and disease specific survival.
Patients with localized STS who were referred to a specialist center after undergoing apparent macroscopic total resection of their tumor had a high incidence of residual tumor in their tumor bed and benefited from undergoing reresection, even if radiation was administered routinely.
接受明显肉眼下肿瘤全切术后就诊于专科中心的局限性软组织肉瘤(STS)患者,残留肿瘤的发生率较高,可能从肿瘤床再次切除中获益。这种再次切除的潜在益处尚未得到充分记录。
分析666例接受明显肉眼下肿瘤全切术后就诊的连续性局限性STS患者的临床病理特征和疾病转归,以阐明再次切除的相对优点。采用精算单因素和多因素方法,比较根据是否接受再次切除,镜下切除切缘阳性或不确定的患者的疾病转归。所有患者均接受辅助放疗。
295例患者接受了肿瘤床再次切除,136例患者(46%)发现残留肿瘤,其中73例患者(28%)存在肉眼可见肿瘤。接受再次切除的患者中,最终切除切缘阴性257例(87%),阳性35例(12%),不确定3例(1%)。未接受再次切除的患者中,最终切缘阴性117例(32%),阳性47例(13%),不确定207例(56%)。接受再次切除的患者5年、10年和15年的局部控制率分别为85%、85%和82%;未接受再次切除的患者,相应的局部控制率分别为78%、73%和73%(P = 0.03)。当将其他预后因素纳入多因素比例风险回归分析时,再次切除仍然是局部控制的重要决定因素。再次切除对无转移生存期和疾病特异性生存期也有类似的有益影响。
接受明显肉眼下肿瘤全切术后转诊至专科中心的局限性STS患者,其肿瘤床残留肿瘤的发生率较高,即使常规进行放疗,再次切除仍使其获益。